80904-86-5

Basic information

• Product Name: AKOS BC-0972
• Synonyms: AKOS BC-0972;CHEMBRDG-BB 4103041;(3-ISOPROPYL-1-ADAMANTYL)AMINE;(3-isopropyl-1-adamantyl)amine(SALTDATA: HCl)
• CAS NO: 80904-86-5
• Molecular Formula: C13H23N
• Molecular Weight: 193.33
• Mol File: 80904-86-5.mol

Chemical Properties

• Boiling Point: 252.7°C at 760 mmHg
• Flash Point: 97.5°C
• Appearance: /
• Density: 1.024g/cm³
• Vapor Pressure: 0.0191mmHg at 25°C
• Refractive Index: 1.542
• CAS DataBase Reference: AKOS BC-0972(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BC-0972(80904-86-5)
• EPA Substance Registry System: AKOS BC-0972(80904-86-5)

Safety Data

• Hazardous Substances Data: 80904-86-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H23N/c1-9(2)12-4-10-3-11(5-12)7-13(14,6-10)8-12/h9-11H,3-8,14H2,1-2H3

Relevant articles and documents

Novel treatment for alzheimer's disease

The present invention concerns a new pharmaceutical composition comprising an antagonist and a co-agonist of the N-methyl-D-aspartate-type glutamate receptor (NMDAR). The inventors found that the co-administration of these two compounds effectively inhibits production of amyloide-β peptide. In patient's suffering from Alzheimer's disease, these peptides are deposited in the extracellular matrix forming neuritic "plaques". Therefore, the present inventors identified a new possibility for prophylaxis and/or treatment of Alzheimer's disease by stopping the continued formation of neuropathological extracellular deposits.

METHODS OF TREATING CNS DISORDERS

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

Pharmaceutical compositions comprising aminoadamantane derivatives

The present invention relates to pharmaceutical compositions comprising 1-aminoadamantane derivatives and a cyclodextrin, which compositions exhibit advantageous safety, convenience, and dosing characteristics. The compositions of the instant invention find particular application in the treatment of various diseases and conditions of the CNS, including those involving the impairment of cognitive function or dementia, such as Alzheimer's disease.

Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors

The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau

Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemic-ally-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.

Adamantane derivatives in the prevention and treatment of cerebral ischemia

A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula STR1 wherein R1 and R2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R3 and R4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R5 is hydrogen or a straight or branched C1 -C6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.